

Special Issue

COVID-19 Vaccination Coverage, Behaviors, and Interaction with Chronic Diseases

Message from the Guest Editor

Several COVID-19 vaccines have been developed, evaluated, and approved for roll out in the population. Clinical trials and real-life data from these vaccines confirm their general safety and efficacy in the population. The vaccines are generally safe and effective to administer to the population except for very rare side effects such as vaccine-induced thrombocytopenia, which occurs in some high-risk individuals who take adenovirus-associated vaccines. Vaccine hesitancy and inadequate vaccine coverage are major problems in the global public health community. Without a sufficient percentage of fully immunized individuals to reach herd immunity, the pandemic will be prolonged and fatal for more people; in addition, the longer the virus continues, the more likely it is to mutate and develop more virulent or infectious strains. The assessment of vaccination status worldwide and population behaviors after vaccination is important to inform public health authorities and decision makers. This Special Issue will present articles discussing vaccine coverage, vaccine roll out, population behaviors and attitudes towards vaccines, and vaccine interaction with existing chronic diseases.

Guest Editor

Dr. Ahmed Negida

Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA

Deadline for manuscript submissions

closed (31 December 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/153803

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).